It was shown that reducing the radioactivity of administered 131I-MIBG may help reduce side effects by minimizing damage to normal cells caused by attacking cancer cells, not only because of the damage caused by β-ray radiation, but also because of the damage caused by activation of immune cells induced by HMGB1 release. Here, HMGB1 is linked to cancer.